AMOEBA announces a major scientific advance on the formulation of its amoeba
Willaertia magna C2c Maky, intended for plant protection.
Lyon (France), February 11th, 2019 - AMOEBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating bacterial risk in water and human
wounds, and a biocontrol product for plant protection, announces a major
scientific advance in the formulation of its amoeba Willaertia magna C2c Maky.
The company has conducted laboratory and greenhouse tests to demonstrate the
efficacy of its amoeba Willaertia magna C2c Maky against downy mildew, a
pathogenic fungus of grapevine, using several amoeba formulations.
In particular, a dry formulation, in powder form, composed of lysed Willaertia
magna C2c Maky amoebae, i.e. dead and in pieces, demonstrated a level of
efficacy comparable to the reference chemical and the living amoeba (see Press
Release dated 4 May 2018).
The active substance in the form of a powdered amoeba lysate constitutes a
major scientific advance since it retains its effectiveness against mildew and
provides many technical and regulatory advantages:
- A storage period of several months instead of a few weeks.
- A volume reduction of several m3 of liquid to a few kilograms of powder.
- Shipment without special conditions of transport from our Chassieu plant to
international destinations such as North America.
- The substance consisting of amoeba lysate eliminates any questioning on a
hypothetical risk to human health of the living amoeba Willaertia magna C2c
Maky. As a reminder, "a so-called 'Trojan horse' effect, with the amoeba
acting as a reservoir for possible pathogenic bacteria" had led to the
non-approval of the living amoeba as a biocidal active substance in Europe
(see Press Releases of 26 April 2018 and 29 November, 2018).
The Company is continuing the research and development on the biocontrol
application in plant protection based on this powdered amoeba lysate and is
considering submitting applications for approval in Europe and the United
States in the first quarter of 2020. Subject to approval of products containing
this active substance by the competent authorities, Amoéba could see the first
marketing authorisations for use against downy mildew in grapevines in the
United States in 2022 and in Europe in 2025. Extensions of use (other diseases
and/or other crops) may be requested and subject to approval by the competent
As a reminder, to date, the company is in the testing phase for biocidal and
plant protection applications and does not market any products.
" Our internal research in association with external expert laboratories has
enabled what I consider to be a major step forward in the world of biocontrol.
Copper, for example in its copper sulphate form commonly known as Bordeaux
mixture, the most widely used anti-mildew agent in Organic Agriculture, has
just undergone significant restrictions on its use, including a sharp reduction
in its authorised dose.
We hope that our active substance will be authorised and can, once on the
market, help our winegrowers and farmers to cope with these restrictions.
Numerous field trials are planned from April in France to check whether the
active substance is effective in real conditions. ", says Fabrice PLASSON.
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. Created in 2010, based in Chassieu (Lyon, France) with a
subsidiary in Canada and in the United States, Amoéba is quoted on the
compartment C of Euronext Paris. The Company is a member of the BPIfrance
Excellence network and is eligible for the PEA-PME SME equity savings plan
setup. More information on www.amoeba- biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
(3 ): BCC Research, "Markets for Advanced Wound Management Technologies,
" Wellesley, MA, 2017
(4 ): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK
Directeur administratif et Financier
04 26 69 16 00
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 27, 2018 (a copy of which is available on
www.amoeba-biocide.com). The forward-looking statements contained in this press
release are also subject to risks not yet known to AMOEBA or not currently
considered material by AMOEBA. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or achievements
of AMOEBA to be materially different from such forward-looking statements.